MinShan Chen
Sun Yat-sen University(CN)Sun Yat-sen University Cancer Center(CN)
Publications by Year
Research Areas
Hepatocellular Carcinoma Treatment and Prognosis, Cancer Genomics and Diagnostics, Liver physiology and pathology, Pancreatic and Hepatic Oncology Research, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion(2019)524 cited
- → Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial(2022)143 cited
- → Triptolide suppresses the growth and metastasis of non-small cell lung cancer by inhibiting β-catenin-mediated epithelial–mesenchymal transition(2021)43 cited
- → Decreased expression of XPO4 is associated with poor prognosis in hepatocellular carcinoma(2010)27 cited
- → Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)(2023)20 cited
- → Transarterial Chemoembolization with Radiofrequency Ablation versus Surgical Resection for Small Late-Recurrence Hepatocellular Carcinoma(2025)16 cited
- → Association between dietary patterns and prognosis of hepatocellular carcinoma in the Guangdong liver cancer cohort study(2020)14 cited
- → Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials(2022)8 cited
- → Effects of percutaneous radiofrequency ablation and repeat hepatectomy for the treatment of solitary recurrent hepatocellular carcinoma with the diameter no more than 3 cm(2011)3 cited
- → Table S4 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)(2023)